Testing an investigational drug for advanced prostate cancer
Treatments studied
Part of Cancer, Kidney & urinary clinical trials.
This Phase 1 trial tests HRS-5041 in people with metastatic castration-resistant prostate cancer (prostate cancer that keeps growing despite lower testosterone). It aims to see if the drug can be given safely and whether it may help control the cancer after prior standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You can sign a consent form (or have your legal representative sign).
- You’re age 18–80, and your sex doesn’t matter.
- Your daily function is good (ECOG 0 to 1, meaning you’re fully active or limited in strenuous activity only).
- Your cancer is prostate adenocarcinoma that has spread, and it has continued growing despite hormone treatment.
- You have already had a taxane chemotherapy and at least one other hormone therapy before joining.
- You cannot have known brain metastases (cancer spread to the brain).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two experimental drugs, HS-20093 and HRS-5041, for men with advanced prostate cancer that has stopped responding to standard hormone therapy. The goal is to see if this new treatment can help control the cancer when other treatments have stopped working.
This Phase 1 study tests the safety, how the drug moves through the body, and whether it shows anti-cancer activity in men with advanced or metastatic prostate cancer. It is designed for people whose cancer has already been treated with certain hormone (androgen receptor) therapies.
This trial tests two new drugs (QLC5508 and QLH12016) alone or together with other treatments for prostate cancer that has spread to other parts of the body. It may be an option if standard treatments have stopped working or caused side effects.
This trial tests a new oral drug, XNW5004, for men with advanced prostate cancer that has spread or stopped responding to standard treatments. It may be given alone or with other therapies like abiraterone, enzalutamide, or chemotherapy, and aims to find better ways to control the disease.
This trial tests a new drug, HRS-4357, against standard treatments for men with a specific type of advanced prostate cancer that has spread and no longer responds to hormone therapy. It aims to see if the new drug works better.
This study tests a combination of two experimental drugs, HRS-2189 and HRS-5041, for men with advanced prostate cancer that has spread and is no longer responding to standard treatments. The goal is to see if the combination is safe and effective in controlling tumor growth.
Hear when a new Advanced Prostate Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.